Sam Brusco, Associate Editor12.08.22
Dexcom has earned U.S. Food and Drug Administration (FDA) clearance for its next-gen Dexcom G7 continuous glucose monitoring (CGM) system for people with all types of diabetes ages two years and older.
“There’s a reason Dexcom has the best-selling real-time CGM on the market,” Kevin Sayer, chairman, president, and CEO of Dexcom told the press. “For more than a decade, we’ve pioneered generation after generation of sensing technology that consistently delivers improved accuracy, reliability and a simpler user experience, giving people greater control of their diabetes. When we set out to design G7, our goal was simple: to make the most powerful, easy-to-use CGM available for people with diabetes, whether they have Type 1 or Type 2. G7 delivers squarely on that promise. And now that it has been cleared by the FDA, we look forward to making G7 commercially available in the coming months.”
New features with Dexcom G7 include:
The company is working closely with insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems.
Dexcom G7 also includes a suite of customizable alerts to warn of high or low glucose levels. Users can share information with loved ones and cares teams as well through remote monitoring and reporting capabilities.
“The first thing that stood out to me when I started using the Dexcom CGM was how easy it was to use,” said Zac Harmon, a Dexcom Warrior and blues musician. “It’s small, non-intrusive and has been the biggest part of my diabetes journey. It feels like it was made just for me, so I can focus more on what’s really important in my life.”
“Dexcom G7 is so simple and easy to use that it should be prescribed to every person with Type 1 and Type 2 diabetes,” said Thomas Grace, MD, a primary care physician in Findlay, Ohio. “G7 isn’t just great for people with diabetes, it’s great for healthcare professionals as well. The integration of Dexcom Clarity into the mobile app provides easy access to retrospective insights about a patient’s glycemic management during in person or telehealth appointments. With its exceptional accuracy and ease of use, I’m confident G7 will be a game changer for my patients.”
Dexcom aims to initiate U.S. launch of Dexcom G7 in early 2023.
“There’s a reason Dexcom has the best-selling real-time CGM on the market,” Kevin Sayer, chairman, president, and CEO of Dexcom told the press. “For more than a decade, we’ve pioneered generation after generation of sensing technology that consistently delivers improved accuracy, reliability and a simpler user experience, giving people greater control of their diabetes. When we set out to design G7, our goal was simple: to make the most powerful, easy-to-use CGM available for people with diabetes, whether they have Type 1 or Type 2. G7 delivers squarely on that promise. And now that it has been cleared by the FDA, we look forward to making G7 commercially available in the coming months.”
New features with Dexcom G7 include:
- 60% smaller wearable with fewer components
- 30-minute sensor warmup
- 12-hour grace period to replace finished sensors
- Redesigned and simplified mobile app
- Improved alert settings to enhance discretion
- Redesigned, smaller optional receiver with a more vibrant, easier to read display
- Worn on back of upper arm for ages two and older or upper buttocks ages two to seventeen
- Smaller plastic components and packaging
The company is working closely with insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems.
Dexcom G7 also includes a suite of customizable alerts to warn of high or low glucose levels. Users can share information with loved ones and cares teams as well through remote monitoring and reporting capabilities.
“The first thing that stood out to me when I started using the Dexcom CGM was how easy it was to use,” said Zac Harmon, a Dexcom Warrior and blues musician. “It’s small, non-intrusive and has been the biggest part of my diabetes journey. It feels like it was made just for me, so I can focus more on what’s really important in my life.”
“Dexcom G7 is so simple and easy to use that it should be prescribed to every person with Type 1 and Type 2 diabetes,” said Thomas Grace, MD, a primary care physician in Findlay, Ohio. “G7 isn’t just great for people with diabetes, it’s great for healthcare professionals as well. The integration of Dexcom Clarity into the mobile app provides easy access to retrospective insights about a patient’s glycemic management during in person or telehealth appointments. With its exceptional accuracy and ease of use, I’m confident G7 will be a game changer for my patients.”
Dexcom aims to initiate U.S. launch of Dexcom G7 in early 2023.
